FluoGuide A/S (FLUO.ST)
- Previous Close
50.00 - Open
50.00 - Bid 49.85 x --
- Ask 50.80 x --
- Day's Range
48.60 - 52.40 - 52 Week Range
41.15 - 99.80 - Volume
4,606 - Avg. Volume
8,860 - Market Cap (intraday)
620.187M - Beta (5Y Monthly) 1.07
- PE Ratio (TTM)
-- - EPS (TTM)
-5.03 - Earnings Date May 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
142.48
FluoGuide A/S, a clinical stage biotechnology company, focused on developing drugs for surgical outcomes by making cancer fluorescent in Denmark. Its lead product candidate is FG001, which is in Phase IIa and IIb for the treatment of high-grade glioma; Phase II clinical trial for the treatment of lung cancer, and head and neck cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. It has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; collaboration with Copenhagen University Hospital; collaboration with Intuitive Surgical, Inc. for robotics surgery in head and neck cancer. FluoGuide A/S was incorporated in 2018 and is headquartered in Copenhagen, Denmark.
fluoguide.comRecent News: FLUO.ST
Performance Overview: FLUO.ST
Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FLUO.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FLUO.ST
Valuation Measures
Market Cap
620.19M
Enterprise Value
603.26M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
31.23
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-13.63
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-84.17%
Return on Equity (ttm)
-171.75%
Revenue (ttm)
423k
Net Income Avi to Common (ttm)
-38.38M
Diluted EPS (ttm)
-5.03
Balance Sheet and Cash Flow
Total Cash (mrq)
21.67M
Total Debt/Equity (mrq)
85.13%
Levered Free Cash Flow (ttm)
-19.2M
Research Analysis: FLUO.ST
Company Insights: FLUO.ST
FLUO.ST does not have Company Insights